Search Results
29 Results Found for “Dravet Syndrome”
Prof. Hideo Yamanouchi discusses the lifelong impact of Dravet syndrome, the importance of adaptive functioning and genetic diagnosis, and how emerging targeted therapies could reshape treatment goals beyond seizure reduction. Dravet syndrome is increasingly understood as a lifelong genetic neurodevelopmental ...
From gene-targeted approaches in Dravet syndrome to positive phase 3 data in focal and generalized seizures, selected presentations at the 16th European Epilepsy Congress highlighted a rapidly evolving epilepsy treatment landscape. Beyond reducing seizure frequency, several studies also explored whether emerging ...
New data shaping diagnosis, treatment strategies and long-term management in epilepsy The American Epilepsy Society Annual Meeting 2025 brought together leading experts to showcase the latest developments in epilepsy research and clinical care. The meeting highlighted significant progress in Dravet Syndrome, ...
The International League Against Epilepsy (ILAE) is a leading global organisation devoted to epilepsy research, education, advocacy and care. Founded in 1909, it now comprises more than 120 national chapters worldwide and serves as a premier resource for clinicians, scientists and public-health ...
Dravet Syndrome UK’s team participated in the 36th International Epilepsy Congress (IEC 2025) in Lisbon, joining clinicians, researchers, pharmaceutical developers and patient advocates focused on Dravet Syndrome and related epileptic encephalopathies. Several key themes emerged that signal progress towards disease-modification, more patient‑centred trials, and enhanced outcome measures beyond simple seizure counts.
Epilepsy affects approximately 1% of the global population, with one-third of patients remaining refractory to medical therapy.1Â Drug-resistant epilepsy (DRE), defined as the failure of two appropriately chosen antiseizure medications (ASMs) to achieve seizure freedom, poses significant risks, including injury and ...
Dravet Syndrome UK has launched the Little Moments Matter Awards, a new programme that celebrates the healthcare, social care and education professionals whose dedication provides vital support to families living with Dravet syndrome. Nominations are open until 31 August 2025, and the winners will be announced at DSUK’s Professionals Conference in November.
In the latest edition of touchREVIEWS in Neurology, we are pleased to present a collection of insightful articles that highlight the current landscape and future directions in neurological research and treatment. Firstly, Rajvinder Karda opens this issue with a compelling ...
Dravet syndrome is a rare genetic disorder that affects approximately 1 in 15,700 individuals. It is one of the most severe epilepsy syndromes of early childhood, with high morbidity and mortality rates.1,2Â It is characterized by seizures that begin in infancy and ...
Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came ...
Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. The impact and the constant care required for someone living with DS has on the patient and their family's quality of life can be huge. ...
Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came ...
Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came ...
We were delighted to talk to Ingrid Scheffer (The University of Melbourne, The Royal Children’s Hospital and Austin Health, Victoria, Australia) regarding the open-label extension study of fenfluramine in patients with Dravet syndrome (Clinical Trial Identifier: NCT02823145). The abstract ‘...
Epilepsy is one of the most common neurological disorders, affecting around 70 million people worldwide.1,2Â Its management is mainly symptomatic, and long-term seizure remission is achieved in most cases.3,4Â One-third of patients, however, continue to experience seizures despite adequate treatment.5Â Remarkably, ...
Welcome to the latest edition of European Neurological Review. The COVID-19 pandemic has brought numerous challenges to neurologists, including how to deal with patients hospitalised with COVID-19 who require neurologic consultations, how we deal with routine neurologic consultations, as well ...
Video produced by and shared with kind authorisation of Dravet Syndrome UK (DSUK). Professor Helen Cross OBE is a globally-recognised authority on Dravet Syndrome and Chair of DSUK's Medical Advisory Board. On Monday 30 March, she took part in a webinar ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
